Novavax, Inc. - Common Stock (NVAX)
$7.32
0.15 (2.09%)
NVAX Stock Quote Delayed 30 Minutes
Novavax: The Party’s Over
Novavax made its vaccine in the traditional way and with an adjuvant to let it cover more people. But people still seem to prefer mRNA vaccines.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
545.22M
PE Ratio
-3.20
EPS
-2.29
Volume (Avg. Vol.)
3.93M
Day's Range
$7.17 - $7.42
52-Week Range
$3.81 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax, Inc. - Common Stock News
Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization
NVAX stock isn't a darling on Wall Street right now, but a rally could be just around the corner as Novavax pursues its global ambitions.
Vaccine Makers Down on FDA Meeting, Novavax Most at Risk
The major covid-19 vaccine makers are all down, anticipating bad-for-business news from the FDA. However, NVAX stock has the most to lose.
Dear Biotech Investors: Novavax’s Comparable Vaccine Matters
Researchers compared Novavax’s vaccine to three others on the market, offering a thorough glimpse of protection from boosters.
Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection
NVAX stock could slide even further as research & development requirements stack up against its balance sheet's capacity.
Novavax Just Hit a New Yearly Low, Here’s How To Buy It Even Lower
NVAX stock is still falling. Get paid for your patience to be a buyer at lower levels by selling expensive puts.
Don’t Bet on New Highs for Novavax Stock
Investors would do well to avoid repeating the mistake of expecting moonshots in NVAX stock. The business may do better, but the stock won't.
4 Top Stock Trades for Wednesday: Dogecoin, NVDA, TLRY, NVAX
Dogecoin, Nvidia, Tilray and Novavax were our top stock trades for Wednesday. Here's how the charts are setting up now.
Why Is Novavax (NVAX) Stock Down Today?
Today, investors in Novavax and NVAX stock appear to be spooked by some key rhetoric from Dr. Anthony Fauci regarding vaccinations.
Novavax Has More Upside Ahead, as Covid-19 Shots Hit the Market
After Covid-19 vaccine delivery and regulatory woes, there is finally more upside than downside risks with NVAX stock.
What to Make of Novavax’s Adolescent Covid-19 Vaccine Move
Novavax stock's foray in the adolescent Covid-19 vaccine market could pay dividends but investors should tread with caution at this time as risk remains.
Novavax’s First Canadian Shipments Are Boosting NVAX Stock
Novavax delivered its first shipments to Canadian health authorities last week, and the news continues to help NVAX stock climb higher today.
Novavax Stock Is Alluringly Attractive at This Stage
Novavax is close to securing FDA approval for its Covid-19 vaccine yet NVAX stock is down since the end of January. What gives?
How to Approach Trading Downtrodden Novavax Today
There are obvious reasons to be bearish on NVAX stock's price chart, but a word to the wise would include the use of this type of put spread.
The Waiting Game Is Wearing Thin for Novavax Investors
If you’re not otherwise engaged with NVAX stock, it’s best to wait until the picture gets clearer on EUA approval.
Novavax’s Success Depends on the FDA’s Decision
While Novavax awaits the FDA approval, the frustration amongst investors is rising and a lot is on stake. Take a small position in NVAX stock.
Why Novavax Stock Is Due for a Comeback Soon
As Novavax has its Covid-19 vaccine authorized in multiple major world markets, NVAX stock is overdue for a re-rating on Wall Street.
Investors Should Not Lose Faith in Novavax
The valuation of NVAX stock is quite attractive while Novavax continues to make progress in many important areas.
Why Is Novavax (NVAX) Stock in the Spotlight Today?
Novavax is once again in the spotlight as China reports near-record numbers of Covid cases. What's going on with NVAX stock?
Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock
NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.
